Health Care • Medical/Dental Instruments
$0.29 ▲ +0.00
(+1.54%)
MKT CAP: $40.7M • VOL: 38.5K
52W L $0 52W H $1
XTNT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $133.9M | $117.3M | $91.3M |
| YoY Revenue Growth % | +14.2% | +28.4% | — |
| Gross Profit | $84.3M | $68.2M | — |
| Gross Margin % | 62.9% | 58.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $7.3M | -$12.1M | -$10.2M |
| Operating Margin % | 5.4% | -10.3% | -11.1% |
| Net Income (GAAP) | $5.0K | -$16.4K | $660 |
| EBITDA (Normalized) | $9.2M | -$8.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $12.5M | -$11.9M | -$9.5M |
| Capital Expenditures (CapEx) | $2.4M | $4.1M | — |
| Free Cash Flow (FCF) | $10.2M | -$16.0M | -$9.5M |
| FCF Margin % | 7.6% | -13.7% | -10.4% |
| Return on Invested Capital (ROIC %) | 12.8% | -16.2% | — |
| Cash & Short-Term Equivalents | $17.1M | $6.2M | — |
| Total Debt (Short + Long Term) | $11.0M | $22.0M | — |
| Total Stockholders' Equity | $51.0M | $43.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XTNT.